130073-98-2

Basic information

• Product Name: 9-amino-1,2,3,4-tetrahydroacridin-2-ol
• Synonyms: 2-acridinol, 9-amino-1,2,3,4-tetrahydro-
• CAS NO: 130073-98-2
• Molecular Formula: C₁₃H₁₄N₂O
• Molecular Weight: 214.2631
• Mol File: 130073-98-2.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 470.2°C at 760 mmHg
• Flash Point: 238.1°C
• Density: 1.315g/cm³
• Vapor Pressure: 1.21E-09mmHg at 25°C
• Refractive Index: 1.726
• CAS DataBase Reference: 9-amino-1,2,3,4-tetrahydroacridin-2-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 9-amino-1,2,3,4-tetrahydroacridin-2-ol(130073-98-2)
• EPA Substance Registry System: 9-amino-1,2,3,4-tetrahydroacridin-2-ol(130073-98-2)

Safety Data

• Hazardous Substances Data: 130073-98-2(Hazardous Substances Data)

Upstream product

• 1684-40-8 tacrine monohydrochloride 
• 202657-76-9 2-hydroxy-9-methoxycarbonylamino-1,2,3,4-tetrahydroacridine 
• 4746-97-8 cyclohexanedione monoethylene ketal 
• 91-56-5 indole-2,3-dione 
• 202657-69-0 2-Hydroxy-1,2,3,4-tetrahydro-acridine-9-carboxylic acid amide 
• 202657-68-9 2-Oxo-1,2,3,4-tetrahydro-acridine-9-carboxylic acid amide 
• 202657-67-8 9-carboxamido-3,4-dihydro-1H-acridin-2-one ethylene acetal 

Relevant articles and documents

Synthesis of 9-Amino-, 9-Aminomethyl-1,2,3,4-tetrahydro- And 1,2,3,4,5,6,7,8-Octahydroacridine Derivatives

This paper describes the synthesis of 9-amino-2- and 4-hydroxy- and 2,4-dihydroxy-1,2,3,4-tetrahydroacridines 2 and of 9-amlnomethyl-1,2,3,4-tetrahydro- and 1,2,3,4,5,6,7,8-octahydroacridines 3 starting from the corresponding 9-carboxamido derivatives. A

Metabolic disposition of tacrine in primary suspensions of rat hepatocyte and in single-pass perfused liver: In vitro/in vivo comparisons

1. Incubations of tacrine (1,2,3,4-tetrahydro-9-acridinamine monohydrochloride monohydrate, THA) with a primary suspension of rat hepatocytes for 2 min resulted in formation of the 1-hydroxy derivative as the major metabolite with smaller amounts of the 2- and 4-hydroxy metabolites. 2. Apparent V(max) and K(m) for THA metabolism were 12.4 ± 3.3 nmol/min/g liver and 0.98 ± 0.34 μM respectively. 3. Incubations of THA for longer time-periods (> 10 min) resulted in irreversible binding of THA-derived radioactivity to hepatocellular protein. The apparent maximal rate of irreversible binding (B(max)) was 76.7 ± 30.5 pmol equivalents bound/h/mg cell protein, whereas the apparent K(b) for binding was 2.8 ± 1.4 μM. 4. The kinetic parameters, V(max) and K(m), were used to predict steady-state extraction ratios (ER(SS)) for various THA input concentrations (C(in)) in single-pass perfused rat liver. At low input concentrations (0.72-0.85 μM; C(in) K(m)), ER(SS) of THA was approximately 1. For higher C(in) (14.05, 20.72, 20.88 μM; C(in) ≥ K(m)), the calculated ER(SS) was markedly decreased with 0.300, 0.296 and 0.261, respectively. 5. The intrinsic clearance of THA (Cl(i)) estimated from in vitro hepatocyte data was 6.7 ml/min/g liver while the apparent oral THA clearance (Cl(oral)) calculated from in vivo rat data was 6.6 ml/min/g liver.